The three-year-old artificial intelligence start-up has drawn investor attention, and money, as its use among doctors, nurses and others skyrockets.
Category: New England Journal of Medicine
-
A New Film at SXSW Warns of the Potential Harm of Microplastics
At SXSW, a documentary traces the arc of plastics in our lives, and highlights evolving research of the potential harm of its presence in our bodies.
-
Severe Frostbite Gets a Treatment That May Prevent Amputation
The F.D.A. recently approved the first therapy for patients in danger of losing their toes, fingers and other exposed parts of the body.
-
Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker’s Study
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
-
Addiction Treatment Medicine Is Vastly Underprescribed, Especially by Race, Study Finds
Black patients with opioid use disorder were far less likely to fill prescriptions for the most effective addiction treatments than white patients. But strikingly few patients of all races got the medicine.
-
F.D.A. Approves New Treatment for Early Alzheimer’s
The New York Times – Business:The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
-
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The New York Times – Business:The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.